The Food and Drug Administration (FDA) has approved Zepbound ® (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea (OSA) in adults with obesity.

Factors associated with higher odds of antiviral receipt include clinical influenza testing and ICU admission.

A case of employment termination of a physician assistant (PA) who had a decade’s old contract with her employer. Was the ...

The researchers noted that there is still an urgent need for more research on the most appropriate diagnostic and treatment options for POI. They emphasized the impact of estrogen deficiency on ...

GSK has made the decision to withdraw Jesduvroq (daprodustat) from the US market. Approved in 2023, Jesduvroq, (HIF-PHI), is ...

Black mothers are faced with a disproportionate number of barriers to breastfeeding compared to other racial and ethnic groups.

The newly approved regimen is expected to simplify administration and potentially reduce medication errors and dose-related reactions.

The prescribing information for Veozah (fezolinetant) has been updated to include a boxed warning regarding the risk of hepatotoxicity, following the Food and Drug Administration’s review of a ...

Dr. Renee Wynn is a doctorally educated, board-certified Women's Health Nurse Practitioner who focuses on perinatal and reproductive health justice. She is an Assistant Professor ...

The Food and Drug Administration (FDA) has approved Steqeyma ® (ustekinumab-stba), a biosimilar to Stelara ® (ustekinumab), for the treatment of various chronic inflammatory diseases in adults and ...

The approval was based on phase 3 data from the randomized, double-blind, placebo-controlled CAHtalyst adult study and CAHtalyst pediatric study.